Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors

Launched by QURIENT CO., LTD. · Jun 27, 2022

Keywords

ClinConnect Summary

This clinical trial is investigating a new treatment combination for patients with advanced cancers, specifically esophageal, gastric, liver, and cervical cancers. The study is testing a medication called Q702 alongside another drug, pembrolizumab, to see how safe it is and whether it can help control the cancer after other treatments have not worked. This trial is currently recruiting participants aged 65 and older who have these types of cancer and have previously received treatment with certain immune therapies.

To be eligible for this trial, participants need to have a confirmed diagnosis of advanced cancer that has continued to grow despite earlier treatments, and they should be in good health overall, with a life expectancy of at least three months. Participants will receive the study drugs and be monitored closely for any side effects and to see how well the treatment works. It’s important to note that individuals who are pregnant, breastfeeding, or have certain medical conditions may not qualify for this trial. If you or someone you know is interested in participating, it’s a good idea to discuss it with a healthcare provider to see if it's a suitable option.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • The participant (or legally acceptable representative if applicable) provides written informed consent for the trial.
• • Subjects with histologically or cytologically confirmed advanced or metastatic esophageal, gastric/GEJ, hepatocellular and cervical cancers who have progressed on treatment with an anti-PD1 or anti PD-L1 monoclonal antibody (mAb) administered either as monotherapy, or in combination with other therapies
• • Have measurable disease per RECIST v 1.1. as assessed by local site investigator/radiology
• • Have an Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
• • Life expectancy of at least 3 months
• Exclusion Criteria:
• • A WOCBP who has a positive urine pregnancy test (within 72 hours) prior to treatment or breast-feeding women
• • Concomitant use of strong inhibitors and inducers of CYP1A2, 2J2, 2C19, 2D6, and 3A4/5 within the timeline duration of five half-lives prior to starting study drug and throughout the trial
• • Concomitant use of sensitive substrates of CYP2C9, 2C19, and 3A4 within the timeline duration of five half-lives prior to starting study drug and throughout the trial
• • Has received prior radiotherapy within 2 weeks of start of study treatment or have had a history of radiation pneumonitis
• • Has had an allogeneic tissue/solid organ transplant